冰川網絡(300533.SZ):擬與掌上雲集簽署約23萬元相關採購合同
格隆匯5月18日丨冰川網絡(300533.SZ)公佈,根據公司業務發展的需求,公司擬與關聯方北京掌上雲集科技發展有限公司(簡稱“掌上雲集”)簽署相關採購合同(包含:《技術服務合同》《隱私檢測銷售合同》)。公司擬接受掌上雲集關於《Android應用加固系統》軟件產品的有償使用授權、《Android應用隱私檢測系統》軟件產品有償使用授權,掌上雲集為公司提供代碼混淆,幫助公司防止核心代碼被反編譯,應用被仿冒,預防API接口暴露,APK包被植入惡意代碼等技術服務,幫助公司應用自動化完成隱私合規檢測並給出整改建議,以及機器無法檢測的隱私合規問題人工介入協助處理,涉及交易金額23萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.